Shorter venetoclax course with azacitidine for untreated acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares taking venetoclax for 7 days versus continuously, along with azacitidine, for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if a shorter course is as effective with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older
- You have acute myeloid leukemia (AML) and are not able to receive intensive chemotherapy due to age or other health conditions
- Your doctor expects you to live at least 12 more weeks
- Your kidney function is adequate (creatinine clearance at least 30 mL/min)
- Your liver function is within trial limits
- You have not had prior treatment for AML or myelodysplastic syndrome (MDS) with certain drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial tests whether a shorter course of venetoclax (a targeted pill) combined with azacitidine (a chemotherapy drug) works as well as the standard longer course for older or frail adults with acute myeloid leukemia (AML). It aims to reduce side effects while keeping the treatment effective.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.